CervoMed Inc., originally Diffusion Pharmaceuticals Inc., is a clinical-stage biotech firm based in Boston, focusing on CNS therapeutics including neflamapimod for neurodegenerative diseases like DLB and Alzheimer's. Incorporated in 2016, the company employs 13 people and its lead product, neflamapimod, is currently in a Phase IIb clinical trial.
CervoMed (CRVO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, CervoMed's actual EPS was -$0.27, beating the estimate of -$0.31 per share, resulting in a 13.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
